Computationally repurposing drugs for breast cancer subtypes using a network-based approach

BMC Bioinformatics

Table 3 Top 20 drugs corresponding to subtype 2

Rank	Drug	Dosage (μm)	Treatment time (h)	Score	Drug type	References
1	Bromocriptine	0.04	24	− 0.93	Approved	[63]
2	Goserelin-Acetate	0.04	24	− 0.8	Approved	[81]
3	Ruxolitinib	10	24	− 0.8	Approved	[51, 52]
4	ICI-185,282	0.04	24	− 0.78	Experimental
5	SDZ-NKT-343	10	24	− 0.75	Experimental
6	Fingolimod	0.04	24	− 0.72	Approved	[82]
7	L-690330	10	24	− 0.71	Investigational
8	PHA-767491	10	24	− 0.68	Experimental	[83]
9	Tolvaptan	10	24	− 0.67	Approved
10	Ribavirin	10	24	− 0.65	Approved	[65]
11	Hymecromone	0.04	24	− 0.64	Investigational	[84]
12	Tranilast	0.04	24	− 0.64	Investigational	[68]
13	Sapitinib	10	24	− 0.64	Investigational	[85]
14	Deferiprone	0.04	24	− 0.63	Approved	[66, 67]
15	Mibampator	0.04	24	− 0.63	Investigational
16	Citrulline	0.04	24	− 0.63	Investigational
17	Lidocaine	0.04	24	− 0.63	Approved	[86, 87]
18	PD-173074	10	24	− 0.62	Experimental	[88]
19	Ibuprofen	10	24	− 0.62	Approved	[89, 90]
20	Garcinol	10	24	− 0.62	Experimental	[91, 92]

ISSN: 1471-2105